About
Eribulin is a synthetic analogue of halichondrin B, a marine natural product, classified as a microtubule dynamics inhibitor. It exerts its anticancer effects by specifically binding to the plus ends of microtubules, thereby inhibiting their polymerization without affecting depolymerization. This unique mechanism leads to the arrest of the cell cycle in the G2/M phase, ultimately inducing apoptosis in cancer cells. Eribulin is primarily used in the treatment of metastatic breast cancer and liposarcoma, particularly in patients who have previously received other chemotherapy regimens.
Its distinct mode of action offers a valuable option for patients with advanced disease, contributing to improved progression-free and overall survival in selected populations. The drug's ability to disrupt microtubule function is critical for preventing cell division and promoting tumor regression, making it an important agent in oncology.
Uses
- Metastatic breast cancer after prior chemotherapy.
- Unresectable or metastatic liposarcoma.
- Advanced breast cancer resistant to other treatments.
- Patients who have received at least two prior chemotherapy regimens for metastatic breast cancer.
Directions For Use
Administer intravenously over 2 to 5 minutes. The dosage and frequency will be determined by your oncologist based on your condition and body surface area.
Benefits
- Unique mechanism of action.
- Effective in metastatic breast cancer.
- Approved for liposarcoma.
- May improve overall survival.
- Offers an option for heavily pretreated patients.
- Administered as a short infusion.
Side Effects
- Fatigue
- Neutropenia
- Alopecia (hair loss)
- Peripheral neuropathy
- Nausea
- Constipation
- Arthralgia
- Myalgia
- Headache
- Anorexia
- Fever
- Weight loss
Safety Measures
- Alcohol - No specific contraindication, but excessive alcohol use may worsen fatigue or liver function, which should be monitored during treatment.
- Pregnancy - Eribulin is embryofetal toxic. It is contraindicated in pregnancy, and women of childbearing potential must use effective contraception.
- Breastfeeding - Due to the potential for serious adverse reactions in breastfed infants, breastfeeding should be discontinued during Eribulin treatment.
- Liver - Dose reduction is recommended for patients with mild or moderate hepatic impairment. Close monitoring of liver function tests is necessary.
- Kidney - Dose reduction is recommended for patients with moderate or severe renal impairment. Renal function should be assessed before and during treatment.
- Lung - No specific lung safety note, but monitor for any new or worsening respiratory symptoms, though not a primary known side effect.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!